CORONAVIRUS UPDATES
Find information and resources about the Research Institute's COVID-19 response
Find information and resources about the Research Institute's COVID-19 response
The Krantz research lab focuses on identifying and characterizing the molecular etiology of syndromic and non-syndromic developmental disorders, birth differences, and intellectual disability, and assesses the genomic implications of the genes and pathways perturbed in these diagnoses. Some of the diagnoses studied, and for which novel gene discoveries have been made, include Cornelia de Lange Syndrome (CdLS), CHOPS syndrome, Pallister-Killian Syndrome (PKS), Alagille syndrome, hearing loss, congenital diaphragmatic hernias, and congenital heart defects.
Novel disease gene discovery have led to the characterization of novel human disorders and has implicated many critical molecular pathways, such as Notch Signaling, Cohesin and the Super Elongation Complex, in human developmental disorders for the first time. The lab uses cellular and animal models to understand the functional consequences of disruption of these genes and the pathways towards identifying potential therapeutic approaches to improving outcomes for the affected individuals. The Krantz lab has also been at the forefront of adapting new genomic technologies to the clinical setting and studying how this evolving, complex and often unclear diagnostic information is understood by, and the impact it has on, the clinicians and families involved.
Director, Individualized Medical Genetics Center
Dr. Krantz's lab identifies and characterizes the molecular etiology of syndromic and non-syndromic developmental disorders. He has identified genes for several genetic conditions (Cornelia de Lange Syndrome, CHOPS syndrome, Alagille syndrome, hearing loss) implicating critical molecular pathways in human disorders for the first time. He has been at the forefront of studying the integration of genomics into clinical settings.